Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR9 | P51686 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | F11 | P03951 | 1/20 | 0.33 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.32 |
| ▸ | BRD4 | O60885 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29776523 | 1.00 | CCR9 (0.35) | CCR9MAPTNPC1F11DGAT1 | |
| SCHEMBL30867555 | 0.83 | CCR9 (0.35) | CCR9MAPTNPC1F11DGAT1 | |
| SCHEMBL29534974 | 0.81 | CCR9 (0.34) | CCR9MAPTNPC1F11DGAT1 | |
| SCHEMBL20455618 | 0.81 | CCR9 (0.34) | CCR9MAPTNPC1F11DGAT1 | |
| SCHEMBL30204246 | 0.80 | CCR9 (0.43) | CCR9MAPTNPC1F11DGAT1 | |
| SCHEMBL26604851 | 0.80 | NPC1 (0.38) | CCR9MAPTNPC1F11DGAT1 | |
| SCHEMBL31414483 | 0.80 | NPC1 (0.38) | CCR9MAPTNPC1F11DGAT1 | |
| SCHEMBL31215668 | 0.79 | MAPT (0.33) | CCR9MAPTNPC1DGAT1 | |
| SCHEMBL24605586 | 0.77 | MAPT (0.34) | CCR9MAPTNPC1DGAT1 | |
| SCHEMBL23909051 | 0.76 | GRM2 (0.31) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CELGENE CORPORATION (US) | 2024-04-18 | — | — | US | disclosed |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY | 2023-01-26 | — | — | US | disclosed |
| EP-4076440-A1 | INHIBITORS OF ENL/AF9 YEATS | The Rockefeller University (US) | 2022-10-26 | — | — | EP | disclosed |
| WO-2022146920-A1 | HETEROCYCLIC COMPOUNDS AND THEIR USE FOR PARASITIC DISEASES | CELGENE CORPORATION (US) | 2022-07-07 | — | — | WO | disclosed |
| WO-2021127166-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-24 | — | — | WO | disclosed |
| WO-2021127166-A1 | INHIBITORS OF ENL/AF9 YEATS | THE ROCKEFELLER UNIVERSITY (US) | 2021-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124444-A1 | Heterocyclic Compounds and Their Use for Parasitic Diseases | CYP11B2, CYP11B1, CYP8B1 | CCR9 1405/4885MAPT 26/4885NPC1 1102/4885 |
| US-20230027198-A1 | INHIBITORS OF ENL/AF9 YEATS | MLLT3, YEATS2, MLLT1 | CCR9 2026/4885MAPT 3429/4885NPC1 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.